Swissmedic Innovation Office

The Swissmedic Innovation Office wants to break new ground to facilitate contact with innovative researchers, research groups and startups, promote Switzerland as research location and facilitate the access to innovative therapies. Swissmedic Innovation Office offers individual on-site meetings to academia, spin-offs and SMEs on the topic of ATMP. This offer wants to enable early dialogue between the regulator and the companies to identify scientific, legal and regulatory challenges early on.

On-Site Meetings

The on-site meetings have a regulatory and scientific focus and cover the various stages of drug development from the manufacturing processes, throughout clinical trials and marketing authorisations. The aim is to support potential applicants in bringing their products to market or to clinical application in a timely manner.

• The consultation is open to everyone but academia, spin-offs and SMEs are prioritised.
• In the current pilot phase, the topics of the Innovation Office are limited to ATMP.
• The consultations are free of charge.
• Swissmedic is bound by official secrecy and the meetings are confidential.

Wyss Zurich and Canton of Zurich

Wyss Zurich and Business and Economic Development of the Canton of Zurich strongly support the Swissmedic initiative. It is a valuable offer for startups and SMEs that can support and accelerate innovation projects. The meetings will take place in the premises of Wyss Zurich. The Business and Economic Development supports communication and promotion of the service.

Swissmedic

Swissmedic is the national authorisation and supervisory authority for drugs and medical products. The agency ensures that only high-quality, safe and effective medical products are available in Switzerland, thus making an important contribution to the protection of human and animal health. As a regulator, Swissmedic has an important role to create the best and clearest possible framework conditions for Switzerland as a research location and attract innovations for patients to Switzerland. It ensures that only high-quality, safe and effective medicines come onto the market in Switzerland and thus protects patients. However, it can also influence the regulatory environment and the way in which researchers and industry work together.